Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Analysts

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has earned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $11.40.

A number of equities research analysts recently weighed in on the company. StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 8th. HC Wainwright decreased their price target on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Maxim Group decreased their price target on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, B. Riley cut Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $16.00 to $2.00 in a research note on Wednesday, August 7th.

Institutional Trading of Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ATNM. Sanders Morris Harris LLC acquired a new stake in Actinium Pharmaceuticals during the first quarter worth about $78,000. The Manufacturers Life Insurance Company acquired a new stake in Actinium Pharmaceuticals in the second quarter valued at approximately $92,000. Renaissance Technologies LLC acquired a new stake in Actinium Pharmaceuticals in the second quarter valued at approximately $142,000. Rhumbline Advisers grew its holdings in Actinium Pharmaceuticals by 23.4% in the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after purchasing an additional 7,525 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in Actinium Pharmaceuticals in the second quarter valued at approximately $356,000. 27.50% of the stock is owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Stock Up 2.4 %

ATNM opened at $1.72 on Friday. Actinium Pharmaceuticals has a 12-month low of $1.33 and a 12-month high of $10.24. The stock’s fifty day moving average price is $1.86. The company has a market cap of $51.23 million, a P/E ratio of -1.01 and a beta of 0.14.

Actinium Pharmaceuticals (NYSE:ATNM) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. On average, equities analysts forecast that Actinium Pharmaceuticals will post -1.38 EPS for the current fiscal year.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).